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The epithelial–mesenchymal transition (EMT) is a crucial
event in wound healing, tissue repair, and cancer progres-
sion in adult tissues. Here, we demonstrate that transform-
ing growth factor (TGF)-b induced EMTand that long-term
exposure to TGF-b elicited the epithelial–myoﬁbroblastic
transition (EMyoT) by inactivating the MEK-Erk pathway.
During the EMT process, TGF-b induced isoform switching
of ﬁbroblast growth factor (FGF) receptors, causing the
cells to become sensitive to FGF-2. Addition of FGF-2 to
TGF-b-treated cells perturbed EMyoT by reactivating the
MEK-Erk pathway and subsequently enhanced EMT
through the formation of MEK-Erk-dependent complexes
of the transcription factor dEF1/ZEB1 with the transcrip-
tional corepressor CtBP1. Consequently, normal epithelial
cells that have undergone EMT as a result of combined
TGF-b and FGF-2 stimulation promoted the invasion of
cancer cells. Thus, TGF-b and FGF-2 may cooperate with
each other and may regulate EMTof various kinds of cells
in cancer microenvironment during cancer progression.
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Introduction
The epithelial–mesenchymal transition (EMT) is a differen-
tiation switch that directs polarized epithelial cells to
differentiate into mesenchymal cells. Recent studies have
proposed that EMT can be classiﬁed into three subtypes
based on the biological context (Thiery and Sleeman, 2006;
Kalluri and Weinberg, 2009; Kalluri, 2009; Zeisberg and
Neilson, 2009). Type 1 EMT involves the transition of primi-
tive epithelial cells to motile mesenchymal cells during
gastrulation and the generation of migrating-neural crest
cells from primitive neuroepithelial cells. This process can
generate mesenchymal cells that have the potential to subse-
quently undergo the mesenchymal–epithelial transition, lead-
ing to the generation of secondary epithelia. Type 2 EMT
involves the transition of secondary epithelial or endothelial
cells to resident tissue ﬁbroblasts and is associated with
wound healing, tissue regeneration, and tissue ﬁbrosis.
Type 2 EMT begins as a part of a repair-associated event
that normally generates ﬁbroblasts for tissue reconstruction
after trauma and inﬂammatory injury. Type 3 EMT occurs in
epithelial carcinoma cells in primary nodules that are transi-
tioning to metastatic tumour cells. This process can affect
both oncogenes and anti-oncogenes, and carcinoma cells that
undergo type 3 EMTcan invade and metastasize, resulting in
cancer progression.
Thus far, nearly all cases of EMT in adult tissues have been
shown to be regulated by extracellular matrix components
and soluble growth factors or cytokines, including epidermal
growth factor, hepatocyte growth factor, ﬁbroblast growth
factors (FGFs), and transforming growth factor (TGF)-bs
(Thiery and Sleeman, 2006; Acloque et al, 2009). Among
these factors, TGF-b and FGFare considered key mediators of
EMTand are frequently and abundantly expressed in various
tumours. TGF-b signalling not only contributes to EMT dur-
ing embryonic development, but also induces EMT in cancer
cells during cancer progression (Moustakas and Heldin,
2007). TGF-b activates Smad proteins and activated Smads
transcriptionally regulate several genes including dEF1, Snail,
Twist, HMGA2, and Ids, which lead to EMT particularly
through the transcriptional repression of E-cadherin
(Zavadil and Bottinger, 2005; Horiguchi et al, 2009).
The E-cadherin repressors that are regulated by TGF-b
appear to function in a cell context-dependent manner, and
dEF1 is one of the most well-characterized factors that is
involved in TGF-b-induced EMT in mouse epithelial cells
(Shirakihara et al, 2007). dEF1 (also known as ZEB1 or
TCF-8) and SIP1 (known as ZEB2) are members of the dEF1
family. dEF1 can bind directly to the E-cadherin promoter and
repress the E-cadherin expression. In addition, dEF1 also
regulates the TGF-b-mediated epithelial–myoﬁbroblastic
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783transition (EMyoT). dEF1 seems to positively regulate the
transcription of a-smooth muscle actin (a-SMA), a represen-
tative myoﬁbroblast marker, by binding to its promoter in
vascular smooth muscle cells (Nishimura et al, 2006).
Among various mammalian FGFs, FGF-2 and FGF-4 are
key regulators of EMT during development and cancer pro-
gression (Strutz et al, 2002; Strutz and Neilson, 2003). FGFs
execute diverse functions by binding and activating members
of the FGF receptor (FGFR) family. There are four FGFR genes
(FGFR1–FGFR4) that encode functional receptors that consist
of three extracellular immunoglobulin domains (Ig-I, Ig-II,
and Ig-III), a single-transmembrane domain, and a cytoplas-
mic tyrosine kinase domain (Eswarakumar et al, 2005).
FGFRs have several isoforms as exon skipping removes the
Ig-I domain. In addition, alternative splicing in the second
half of the Ig-III domain in FGFR1–FGFR3 produces the IIIb
(FGFR1IIIb–FGFR3IIIb) and IIIc (FGFR1IIIc–FGFR3IIIc) iso-
forms that have distinct FGF-binding speciﬁcities and are
predominantly expressed in epithelial and mesenchymal
cells, respectively. FGF-2 binds preferentially to the IIIc iso-
forms, whereas FGF-7 and FGF-10 bind exclusively to the IIIb
isoforms. FGF-2 is highly expressed in wounds and tumour
tissues. However, it has not been determined how FGF-2
transmits signals to induce EMTand promote cancer progres-
sion because epithelial cells typically express the FGFRIIIb
isoforms, which do not bind to FGF-2. Recently, it was
reported that advanced cancer cells overexpress FGFR1IIIc
(Foster et al, 1999; Acevedo et al, 2007), but it is still
unknown how epithelial cells and cancer cells upregulate
the expression of the FGFRIIIc isoforms.
In the present study, we investigated the properties of EMT
induced by TGF-b in cooperation with FGFs. TGF-b induced
EMT, and prolonged treatment with TGF-b induced EMyoT.
During TGF-b-mediated EMT, TGF-b altered the sensitivities
of cells from FGF-7 to FGF-2 through FGFR isoform switch-
ing. In addition, FGF-2 prevented TGF-b-mediated EMyoTand
enhanced EMT with more aggressive characteristics that
resemble those of activated ﬁbroblasts. Moreover, the cells
generated through EMT mediated by FGF-2 and TGF-b facili-
tated cancer cell invasion, when the cells undergoing EMT
were mixed with cancer cells. Therefore, TGF-b and FGF-2
cooperate with each other and may regulate the EMT of
various kinds of cells in cancer microenvironment.
Results
FGFR isoform switching during TGF-b-induced EMT
Although the FGFRIIIc isoforms are not predominantly ex-
pressed in epithelial cells, their expression and FGF-2 expres-
sion have been correlated with cancer progression. We
hypothesized that TGF-b primes FGFR isoform switching in
cells undergoing EMTand subsequently alters the sensitivity
of cells to FGF ligands. To verify this possibility, we ﬁrst
examined the mRNA proﬁles of FGFR variants in response to
TGF-b by quantitative RT–PCR analyses. FGFR1 mRNA gra-
dually increased to B3.5-fold in mouse normal mammary
epithelial NMuMG cells 24h after TGF-b stimulation, whereas
FGFR2 mRNA levels decreased over this time period
(Figure 1A). Conventional RT–PCR analyses using isoform-
speciﬁc primers revealed that FGFR1 upregulated by TGF-b
was FGFR1IIIc (the mesenchymal isoform), whereas the
FGFR2 downregulated by TGF-b was FGFR2IIIb (the epithelial
isoform) (Figure 1B). FGFR1IIIb, FGFR2IIIc, FGFR3, and
FGFR4 were not clearly detected in NMuMG cells. The
isoform switching of FGFRs was also detected in mouse
mammary gland epithelial Eph4 cells that underwent EMT
by TGF-b. Interestingly, the addition of FGF-2 to TGF-b-
treated cells sustained expression of FGFR1 and FGFR2 at
higher and lower levels, respectively, for 72h (Figure 1C).
Consistent with the changes in the mRNA expression proﬁles
of the FGFR isoforms, Erk phosphorylation was observed in
NMuMG cells in response to FGF-7, but not FGF-2, whereas
Erk phosphorylation was observed in TGF-b-pretreated cells
in response to FGF-2, but not FGF-7 (Figure 1D). These
ﬁndings indicate that TGF-b primes isoform switching of
FGFRs during EMT and thereby changes the sensitivities of
cells from FGF-7 to FGF-2.
Activated phenotype of cells generated by FGF-2 and
TGF-b treatment
Next, we determined whether FGF-2 enhanced TGF-b-in-
duced EMT after TGF-b-induced FGFR isoform switching,
because previous studies have shown that TGF-b-induced
EMT can be enhanced with oncogenic signals or growth
factors (Horiguchi et al, 2009). To examine this possibility,
NMuMG cells were continuously exposed to TGF-b, FGF-2, or
both for several days. As we previously reported (Shirakihara
et al, 2007), the morphology of NMuMG cells clearly changed
from a cobblestone-like shape to a ﬁbroblastic spindle shape
upon prolonged TGF-b treatment, whereas cells treated with
FGF-2 alone did not exhibit morphological changes
(Figure 2A). Compared with cells treated with TGF-b alone,
the addition of FGF-2 to TGF-b-treated cells led to drastic
changes in cell morphology and actin ﬁbre formation that are
typical of ﬁbroblastic differentiation (Figure 2A and B).
Next, cell motility was examined using a wound closure
assay with NMuMG cells. After treating with TGF-b, FGF-2, or
both for 4 days, the cells were wounded by scratching and
were then analysed after 12h. Figure 2C shows that NMuMG
cells treated with TGF-b alone had slightly enhanced cell
motility, compared with non-treated cells or FGF-2-treated
cells. On the other hand, treating with TGF-b and FGF-2
strongly promoted the motility of NMuMG cells within only
12h. Similar to their ability to enhance migration, combined
TGF-b and FGF-2 treatment remarkably promoted the
invasion of NMuMG cells in an in vitro invasion assay
(Figure 2D). As one of the most characteristic features of
ﬁbroblasts is their ability to degrade extracellular matrix, this
property was also determined by a collagen gel degradation/
contraction assay (Mikko et al, 2008). Cells were pretreated
with TGF-b, FGF-2, or both and then suspended in a collagen
type I gel. After the collagen had solidiﬁed, the gel was
detached from the sides and bottoms of the dishes and ﬂoated
in media containing ligands for 48h. There was no signiﬁcant
degradation of the collagen gel in either the control or FGF-2-
treated cells, but the volume of the collagen gel was reduced
by B60% in cells treated with TGF-b (Figure 2E). More
importantly, the cells treated with TGF-b and FGF-2 drasti-
cally decreased the volume of collagen gel by B30%, and
these changes were inhibited by the matrix metalloprotease
inhibitor, GM6001. Gelatin zymography further showed that
MMP9 activity was enhanced by TGF-b and FGF-2, compared
with that by TGF-b alone (Figure 2F). These ﬁndings
suggest that NMuMG cells treated with TGF-b alone reveal
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FGF-2 exhibit EMT and more aggressive characteristics that
resemble those of activated ﬁbroblasts.
Myoﬁbroblastic differentiation by prolonged TGF-b
treatment
To biochemically discriminate between cells that were con-
tinuously exposed to TGF-b alone and those exposed to TGF-b
and FGF-2, we examined the expression of representative
TGF-b-target genes based on our previous study (Kondo et al,
2004). The phosphorylation levels of Smad2 or Smad1/5/8
were not different, and expression levels of some TGF-b-
target genes, including Smad7 and ﬁbronectin, were not
affected by the addition of FGF-2, indicating that FGF-2 did
not affect general TGF-b-Smad signalling (Supplementary
Figure S1A and B). Interestingly, the mRNA expression
levels of well-known myoﬁbroblast markers, a-SMA and
calponin, were increased in TGF-b-treated cells, and a-SMA
expression was conﬁrmed in the cells by immunohisto-
chemical analyses (Figure 3A and B), suggesting that TGF-b
induced EMyoT. Conversely, the addition of FGF-2 to TGF-
b-treated cells markedly decreased the expression of a-SMA
and calponin (Figure 3B and C), although the levels of the
representative EMT marker, E-cadherin, were repressed by
TGF-b and unaffected by addition of FGF-2 (Figure 3C;
Supplementary Figure S1C). Inhibition of FGF-2 signalling
by SU5402 or short interfering RNA (siRNA)-mediated knock-
down of FGFR1IIIc by its speciﬁc siRNAs did not obviously
alter the expression of E-cadherin regulated by TGF-b
(Figure 3C; Supplementary Figure S1D), suggesting that
autonomously secreted ligands to FGFR1IIIc exhibit only
limited effects on TGF-b-induced EMT. In addition, these
ﬁndings were not restricted to NMuMG cells, and were also
observed in another epithelial cell line a-TN4 (Supplemen-
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Figure 1 Isoform switching of FGFRs during TGF-b-induced EMT. (A) The kinetics of FGFR1 and FGFR2 expression were examined in NMuMG
cells treated with 1ng/ml TGF-b for the indicated periods by quantitative RT–PCR analysis. The ratio of the mRNA levels in TGF-b-treated cells
compared with non-treated cells is shown. Each value represents the mean±s.d. of duplicate determinations from a representative experiment.
Similar results were obtained in at least three independent experiments. (B) Expression of the alternatively spliced forms of FGFR1 and FGFR2
was examined by RT–PCR using RNA samples from NMuMG cells treated with TGF-b for 36h. A schematic illustration of the primers is shown
at the top. The primers for the IIIb and IIIc isoforms were the sp1–ap1 pair and sp2–ap1 pair, respectively. Ig, extracellular immunoglobulin-like
domain; KD, kinase domain. FGFR3 and FGFR4 were not detected in NMuMG cells by quantitative RT–PCR. (C) Regulation of FGFR1
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experiments. (D) Erk1/2 phosphorylation (p-Erk1/2) by FGF-2 or FGF-7 was examined by immunoblot analysis. NMuMG cells were
preincubated with or without TGF-b for 2 days and then stimulated with 30ng/ml FGF-2 or 30ng/ml FGF-7 for 15min. F2, FGF-2; F7, FGF-7.
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prolonged TGF-b treatment induces the differentiation of
epithelial cells into myoﬁbroblastic cells, and that FGF-2
inhibits the TGF-b-mediated EMyoT.
FGF stimulation leads to tyrosine phosphorylation of
FGFR, the recruitment of multiple complexes with adaptor
proteins, and activation of the MEK-Erk, phosphoinositide 3
kinase (PI3K) and phosphatidylinositol-speciﬁc phospholi-
pase C (PLC) g pathways. To determine how FGF-2 inhibits
TGF-b-mediated EMyoT, we used several inhibitors, including
SU5402 for FGFR1, U0126 for MEK 1 and 2, PI-103 for PI3K,
and U73122 for PLC. Among these inhibitors, SU5402 and
U0126 clearly inhibited the effects of FGF-2 and restored TGF-
b-induced a-SMA expression and cell morphology, while
neither PI-103 nor U73122 signiﬁcantly affected these cells
(Figure 3D and E). More importantly, TGF-b reduced the
levels of Erk phosphorylation, which was accompanied by
a reciprocal induction of a-SMA, whereas the addition of
FGF-2 returned the Erk phosphorylation levels to baseline
(Figure 3F). The cells expressing a-SMA had weaker Erk
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determined by immunohistochemical analyses (Supplemen-
tary Figure S2C). Thus, these ﬁndings suggest that Erk
inactivation by TGF-b results in a-SMA induction and that
restored Erk activation by FGF-2 is required to prevent the
induction of a-SMA by TGF-b.
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interaction
We further examined how FGF-2-induced Erk activation
suppressed the induction of a-SMA by TGF-b. Based on a
previous report and our previous study (Nishimura et al,
2006; Shirakihara et al, 2007), we focused on the dEF1 family
proteins, dEF1/ZEB1 and SIP1/ZEB2. After conﬁrming that
speciﬁc siRNAs successfully knocked down dEF1 and SIP1 at
both the mRNA (Figure 4A) and protein levels (Shirakihara
et al, 2007), we found that SIP1 siRNA did not affect the
induction of a-SMA (Figure 4B). However, in cells transfected
with dEF1 siRNAs, TGF-b-mediated a-SMA upregulation was
signiﬁcantly reduced to a level similar to that obtained with
the addition of FGF-2 (Figure 4B and C). More interestingly,
FGF-2 did not affect the expression of dEF1 at either the
mRNA or protein level (Figure 4A and lower panels in
Figure 4E), nor did it affect the expression of microRNA-
200b that directly targets dEF1 (Supplementary Figure S2D)
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expression levels of dEF1 (A, left), SIP1 (A, right), and a-SMA (B). NC, control siRNA. Each value represents the mean±s.d. of duplicate
determinations from a representative experiment. Similar results were obtained at least three independent experiments. (C) After transfection
with different types of siRNAs against dEF1 (dEF1-B and dEF1-C), a-SMA induction by TGF-b was evaluated by immunoblot analysis. a-Tubulin
was used as a loading control. The ratio of dEF1 or a-SMA to a-tubulin was validated by densitometric analysis and shown at the lower panels.
NC, control siRNA; Tb, TGF-b; F2, FGF-2. (D) NMuMG cells transfected with control siRNA (NC) or two different types of CtBP1 siRNAs (#1
and #2) were stimulated with TGF-b, FGF-2, or both for 60h as indicated. After measuring the protein concentrations, the cell lysates were
examined by immunoblot analysis. a-Tubulin was used as a loading control. (E) After NMuMG cells were incubated in culture media
containing 10% FBS for 4 days with the indicated ligands, cell lysates from B1 10
6 cells were examined for protein concentrations and then
subjected to immunoprecipitation with normal rabbit IgG (NRS) or an anti-dEF1 antibody. Copuriﬁed CtBP1 was detected by immunoblotting
with an anti-CtBP1 antibody (top panel). The expression levels of dEF1, CtBP1, and a-tubulin in the same lysates were veriﬁed by
immunoblotting (lower three panels). The ratio of dEF1 to a-tubulin was validated by densitometric analysis and shown at the bottom.
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required for the TGF-b-mediated induction of a-SMA and that
FGF-2 reduces a-SMA expression without affecting the levels
of dEF1 that are upregulated by TGF-b. Thus, the function of
dEF1 is regulated by mechanisms other than those involved
in regulating transcription or protein stability.
The transcriptional function of dEF1 is regulated through
interactions with CtBP1, C-terminal binding protein 1
(Chinnadurai, 2009; Vandewalle et al, 2009). We also found
that the inhibitory effect of FGF-2 on TGF-b-induced a-SMA
expression was abolished by knocking down CtBP1, resulting
in restored a-SMA expression, whereas E-cadherin repression
by TGF-b was not affected (Figure 4D). Moreover, endogen-
ous CtBP1 coimmunoprecipitated with endogenous dEF1
(Figure 4E). TGF-b treatment reduced the interaction between
CtBP1 and dEF1, while the addition of FGF-2 restored this
interaction to a level similar to that in untreated cells
(Figure 4E). Inhibition of the MEK-Erk pathway with U0126
and PD98059 decreased this interaction compared with that
in the cells treated with TGF-b and FGF-2 (Supplementary
Figure S3A). To further deﬁne this interaction, we transiently
transfected HEK-293T cells with expression plasmids encod-
ing Myc-tagged dEF1 and FLAG-tagged CtBP1. The inter-
action between dEF1 and CtBP1 was conﬁrmed in
overexpressing HEK-293T cells (Supplementary Figure S3B).
A CtBP1 mutant that harbours mutations in conserved sites
putatively phosphorylated by MAP kinases also interacted
with dEF1. This interaction was enhanced by FGF-2 stimula-
tion and repressed by U0126 (Supplementary Figure S3B). In
addition, FLAG-CtBP1 that was immunoprecipitated from
FGF-2-treated cells exhibited an enhanced interaction with
Myc-dEF1 compared with that from non-treated cells in an in
vitro binding assay (Supplementary Figure S3C). To examine
whether the association between CtBP1 and dEF1 was regu-
lated by Erk kinase-mediated phosphorylation of CtBP1, we
used alkaline phosphatase, which is widely used in in vitro
dephosphorylation assays. Dephosphorylation of immuno-
precipitated FLAG-CtBP1 by alkaline phosphatase slightly
decreased its ability to interact with Myc-dEF1
(Supplementary Figure S3C). Thus, these ﬁndings indicate
that the interaction between CtBP1 and dEF1 is highly
dependent on MEK-Erk activation and that CtBP1 phosphor-
ylation slightly enhances its ability to interact with dEF1.
Therefore, TGF-b upregulates the expression of dEF1 and
inactivates the MEK-Erk pathway to facilitate the dissociation
of dEF1 from CtBP1, which induces a-SMA expression.
Conversely, the addition of FGF-2 to TGF-b-treated
cells activates the MEK-Erk pathway to enhance the interac-
tion between dEF1 and CtBP1, which represses a-SMA
induction.
Differentiation of epithelial cells to myoﬁbroblastic cells
from ﬁbroblastic cells through TGF-b-induced EMyoT was
highly dependent on dEF1 (Figure 4). To elucidate the mole-
cular mechanism by which ﬁbroblastic cells differentiate to
activated ﬁbroblastic cells by combination of TGF-b with
FGF-2, we performed DNA microarray analysis and knocked
down dEF1 and CtBP1 using their speciﬁc siRNAs. During
this process, FGF-2 altered the broad transcriptional program
mediated by TGF-b. Among them, Twist, a representative of
EMTregulators, was included in the program and remarkably
upregulated by combination of TGF-b and FGF-2
(Supplementary Figure S4A). In addition, siRNA-mediated
knockdown of dEF1 did not affect the migratory behaviour
of cells (Supplementary Figure S4B), indicating that dEF1 is
dispensable for differentiation into activated ﬁbroblastic cells.
Conversely, silencing CtBP1 in cells treated with FGF-2 and
TGF-b affected some properties, including the induction of
a-SMA and calponin, cell migration and cell invasion (see
Figure 4D and Supplementary Figure S4C and D), while
MMP9 activity and E-cadherin expression were not affected
by CtBP1 siRNA (see Figure 4D and Supplementary Figure
S4E). These ﬁndings thus suggest that CtBP1 mediates some
properties of EMT induced by TGF-b and FGF-2, and that
other EMTregulators following TGF-b-mediated upregulation
of dEF1 may be important to differentiate into activated
ﬁbroblastic cells.
Effects of cells undergoing EMT by TGF-b and FGF-2 on
the invasion of cancer cells
TGF-b induced differentiation of epithelial NMuMG cells into
two types of mesenchymal cells: one was a-SMA-positive
myoﬁbroblastic cells (thereafter denoted NMu-b cells) gener-
ated through EMyoT by TGF-b alone, and the other was
activated ﬁbroblastic cells (NMu-fb cells) generated through
EMT by both TGF-b and FGF-2. To determine the biological
functions of these cells, the cells were mixed with human
breast cancer MCF-7 cells expressing green ﬂuorescent pro-
tein (MCF-7-GFP) and seeded on collagen gels to examine the
invasive properties of the cancer cells (Margulis et al, 2005;
Higashikawa et al, 2007; Ikebe et al, 2007; Horiguchi et al,
2009). In cultures containing NMuMG cells alone, TGF-b
slightly enhanced the invasive properties of the cells com-
pared with non-treated cells due to changes in the NMu-b
cells, and the addition of FGF-2 and TGF-b further promoted
the invasion of the cells due to changes in NMu-fb cells
(Figure 5A). On the other hand, MCF-7-GFP cells seeded on
collagen gels with or without NMuMG cells spontaneously
invaded into the collagen (Figure 5B-i, ii, vii, and viii). This
invasion was slightly, but not signiﬁcantly, enhanced in MCF-
7-GFP cells treated with TGF-b and TGF-bþFGF-2 (Figures
5B-iii, iv, v, and vi). When MCF-7-GFP cells were mixed
with NMu-b cells and treated with TGF-b, their invasion
was slightly enhanced compared with those mixed with
NMuMG cells (Figure 5B-ix and x). More interestingly,
MCF-7-GFP cells that were mixed with NMu-fb cells and
treated with TGF-bþFGF-2 invaded more deeply into the
collagen gels (Figure 5B-xi and xii). Under these conditions,
proliferation of MCF-7 was suppressed in the presence of
TGF-b, as determined by immunostaining with anti-Ki67
antibody (Supplementary Figure S5), suggesting that en-
hanced invasive behaviour does not result from cell prolif-
eration of MCF-7 cells. When MCF-7 cells were cocultured
with NMu-fb cells and treated with TGF-b and FGF-2, the cells
exhibited spindle shapes with enhanced invasive behaviour,
which was repressed by CtBP1 siRNA (Figure 5C;
Supplementary Figure S4F). Therefore, the cells that have
undergone EMT by TGF-b and FGF-2 promoted invasion of
MCF-7 cells more potently than the a-SMA-positive cells that
were generated by TGF-b-induced EMyoT.
Discussion
In the present study, we found that TGF-b primes FGFR
isoform switching and generates ﬁbroblastic cells by EMT,
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to myoﬁbroblastic cells through EMyoT in the presence of
TGF-b and to activated ﬁbroblastic cells through EMT in the
presence of FGF-2 and TGF-b (Figure 6). During these pro-
cesses, dEF1 has critical roles in determining the direction of
the differentiation. First, transcriptional upregulation of dEF1
and SIP1 by TGF-b is essential to generate ‘ﬁbroblastic cells’
through EMT that is incomplete, as we previously reported
(Shirakihara et al, 2007). Second, increased levels of dEF1 are
required to induce a-SMA during the differentiation into
‘myoﬁbroblastic cells’ through EMyoT. Third, FGF-2 en-
hances TGF-b-induced EMT and generates ‘activated ﬁbro-
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tween dEF1 and CtBP1 phosphorylated through the FGF-2-
activated MEK-Erk pathway (Figure 6). The activated ﬁbro-
blastic cells generated by FGF-2 in combination with TGF-b
promote the invasion of cancer cells. Thus, TGF-b and FGF-2,
which are abundantly present in tumours, may regulate not
only the EMT of cancer cells as they acquire metastatic
properties but also that of normal epithelial cells as they
promote the invasion of cancer cells.
Isoform switching of FGFRs during TGF-b-induced EMT
In the present study, we found that NMuMG cells were
sensitive to FGF-7 because they expressed the cognate recep-
tor FGFR2IIIb, whereas TGF-b-pretreated NMuMG cells be-
came sensitive to FGF-2 as FGFR2IIIb was replaced to
FGFR1IIIc (Figure 1). The molecular mechanism by which
TGF-b controls isoform switching has not been elucidated.
Recently, it was reported that RNA-binding proteins, ESRP1
and ESRP2, coordinate to promote a cell-type speciﬁc splicing
program, which results in isoform switching from FGFR2IIIb
to FGFR2IIIc (Warzecha et al, 2009). However, during TGF-b-
induced EMT, FGFR2IIIb changed to FGFR1IIIc but not to
FGFR2IIIc. Thus, in addition to ESRPs, other transcriptional
factors may be involved in the process of TGF-b-mediated
isoform switching. Moreover, the addition of FGF-2 to
TGF-b-treated cells resulted in sustained expression of
FGFR1IIIc at higher levels (Figure 1C). Previous studies
reported that FGF-2 induced EMT in some cells through the
expression of Snail (de Frutos et al, 2007), and that FGFR1IIIc
expression was associated with EMTand correlated with the
progression of several advanced cancers (Acevedo et al,
2007). As TGF-b is frequently overexpressed in cancer cells,
FGFR1IIIc expression and the effects of FGF-2 during cancer
progression may be regulated by TGF-b that is autonomously
secreted from cancer cells. Therefore, inhibition of TGF-b
signalling may ameliorate cancer progression through
FGF-mediated EMT, and thus may be a useful therapeutic
target.
Figure 5 Effects of TGF-b and FGF signalling on cancer cell invasion. (A) NMuMG cells were pretreated with 1ng/ml TGF-b (NMu-b) or both
1ng/ml TGF-b and 30ng/ml FGF-2 (NMu-fb) for 2 days and then seeded on collagen gels. After 1 week, the gels were ﬁxed, embedded in
parafﬁn, and stained with HE. Bars represent the median for each category from a representative experiment. Similar results were obtained in
two independent experiments. Scale bar indicates 100mm. (B) MCF-7-GFP cells were seeded on a collagen gel and treated with 1ng/ml TGF-b
or 30ng/ml FGF-2þTGF-b (i–vi). NMuMG cells were pretreated with 1ng/ml TGF-b (NMu-b cells) or 30ng/ml FGF-2 together with TGF-b
(NMu-fb cells) for 2 days, and mixed with MCF-7-GFP cells in the presence or absence of TGF-b and TGF-bþFGF-2 (vii–xii). After 7 days, the
gel was ﬁxed and stained with HE (i, iii, v, vii, ix, xi). GFP was detected by confocal laser scanning microscopy (ii, iv, vi, viii, x, xii). Scale bars
indicate 100mm. (xiii, xiv) Statistical analyses were performed using a non-parametric Mann–Whitney U test. The median migration distance of
cells was signiﬁcantly different at P40.05 between the two groups of MCF-7 cells (non-treatment versus TGF-bþFGF-2 treatment, and TGF-b
treatment versus TGF-bþFGF-2 treatment) and at Po0.001 between the two groups of MCF-7 cells mixed with the indicated cells (NMuMG
cells versus NMu-fb cells and NMu-b cells versus NMu-fb cells). Bars represent the median for each category from a representative experiment.
(C) NMuMG cells were cultured for 4 days in the absence or presence of TGF-b or both TGF-b and FGF-2, and then seeded into collagen gel-
loaded culture inserts with MCF-7-GFP cells, which had been cocultured in cell culture inserts with NMuMG cells. The GFP-positive cells that
had invaded to the opposite side were ﬁxed and photographed (left), and typical morphology of the cells were counted and quantiﬁed (right).
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Figure 6 Schematic illustration of EMT induction by TGF-b and FGF-2. ‘Epithelial cells’ differentiate into ‘ﬁbroblastic cells’ through EMT
induced by TGF-b, and further differentiate into a-SMA-positive ‘myoﬁbroblastic cells’ through EMyoT. When FGF-2 is present in this process,
FGF-2 induces the differentiation of (myo)ﬁbroblastic cells to ‘activated ﬁbroblastic cells’. The red dot in CtBP1 indicates phosphorylation.
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pathway
It has been reported that CtBP1 is a corepressor for dEF1
(Chinnadurai, 2009). In the present study, we found that the
interaction between dEF1 and CtBP1 was enhanced by FGF-2
and decreased by inhibiting the MEK-Erk pathway (Figure 4E;
Supplementary Figure S3B). CtBP1 is localized in the nucleus
of the cells. In addition, in vitro dephosphorylation of
immunoprecipitated CtBP1 by alkaline phosphatase treat-
ment slightly decreased its interaction with Myc-dEF1
(Supplementary Figure S3C), suggesting that phosphoryla-
tion of CtBP1 is partially involved in the interaction with
dEF1. It has been reported that PKA and JNK phosphorylate
CtBP1 at threonine 144 and serine 422, respectively (Wang
et al, 2006; Dammer and Sewer, 2008). Moreover, we identi-
ﬁed another consensus sequence (S/T-P site) at threonine 311
in human CtBP1 that is putatively phosphorylated by Erk
kinase, and this site is also conserved in mouse CtBP1 and in
the corresponding site of CtBP2. When these putative phos-
phorylation sites in CtBP1 were mutated to alanine residues,
the mutations did not affect the interaction between CtBP1
and dEF1 (Supplementary Figure S3B). Recently, novel phos-
phorylation sites were identiﬁed by mass spectrometry
(Merrill et al, 2010). Thus, in addition to the phosphorylation
sites of 311 and 422, we mutated these phosphorylation sites
and have performed coimmunoprecipitation assay. However,
FGF-2-dependent complex formation between dEF1 and
CtBP1 mutants with alteration of these phosphorylation
sites (100, 144, 158, and 176) was not considerably altered,
compared with that between dEF1 and CtBP1
(Supplementary Figure S3D). These ﬁndings suggest that
phosphorylation of CtBP1 at unidentiﬁed site(s) by the
MEK-Erk pathway regulates this interaction. Alternatively,
other MEK-Erk-dependent post-translational modiﬁcations
of CtBP1, such as methylation, oxidation, and acetylation,
which are inhibited by U0126, may regulate the association
with dEF1.
dEF1 has multiple consensus sites for phosphorylation by
Erk kinases (Costantino et al, 2002), and the bands corre-
sponding to dEF1 by SDS–PAGE migrated faster after in vitro
dephosphorylation by alkaline phosphatase (see top right
panel in Supplementary Figure S3E). In addition, dEF1 was
acetylated in the CtBP1 interaction domain to regulate CtBP1
binding (Postigo et al, 2003). Thus, although in vitro depho-
sphorylation of dEF1 did not affect its ability to bind to CtBP1
(Supplementary Figure S3E), the possibility that post-transla-
tional modiﬁcation of dEF1 regulates the interaction with
CtBP1 could not be completely excluded.
Although the formation of dEF1–CtBP1 complexes inhib-
ited the induction of a-SMA, the molecular mechanism by
which TGF-b induces a-SMA was not fully determined in the
present study. It was previously reported that dEF1 has
important roles in the TGF-b-mediated induction of a-SMA
in vascular smooth muscle cells. dEF1 physically interacted
with SRF, serum response factor, and these complexes syner-
gistically activated a-SMA expression by directly binding to
the promoter of the a-SMA gene (Nishimura et al, 2006). We,
however, found that dEF1 did not form a complex with SRF,
and TGF-b repressed the protein levels of SRF in NMuMG
cells (Supplementary Figure S3F). It appears likely that CtBP1
constitutively binds to dEF1 and suppresses the transcrip-
tional regulatory function of dEF1 under unstimulated
conditions, whereas TGF-b upregulates dEF1 expression
levels and reduces CtBP1 modiﬁcations by inactivating the
MEK-Erk pathway, leading to the dissociation of CtBP1 from
dEF1. Subsequently, dEF1 can regulate a-SMA induction in
association with SRF or unidentiﬁed protein(s) (Figure 6).
The a-SMA-promoter construct responded to TGF-b stimula-
tion as well as dEF1 overexpression in reporter assays
(Supplementary Figure S3G). CtBP1 partially inhibited this
a-SMA-reporter activity induced by dEF1, while CtBP1 failed
to inhibit the activity induced by dEF1 mutant that does not
bind to CtBP1 (Furusawa et al, 1999). Thus, dEF1 acts as an
activator or derepressor, and is indispensable for a-SMA
induction by TGF-b in NMuMG cells. However, it should be
determined in the future whether dEF1 acts as an activator or
derepressor of a-SMA transcription.
Differentiation of normal epithelial cells by cancer cells
in a cocultivation system
In cancer microenvironments, both TGF-b and FGF-2 are
frequently secreted from advanced cancer cells and abun-
dantly expressed in tumour tissues (Memarzadeh et al,2 0 0 7 ;
Massague, 2008; Padua and Massague, 2009). We found that
cocultivating normal epithelial cells with mouse breast can-
cer JygMC(A) cells, which secrete TGF-b, led to EMyoT of
epithelial cells, accompanied by the induction of a-SMA
(Supplementary Figure S6A and B), while cocultures with
mouse breast cancer 4T1 cells, which express higher
levels of FGF-2 mRNA than JygMC(A) cells (Supplementary
Figure S6C), failed to yield a-SMA-positive NMuMG cells
(Supplementary Figure S6B). Both breast cancer cells auton-
omously secreted TGF-b ligands. Therefore, these ﬁndings
indicate that TGF-b secreted from cancer cells induces the
differentiation of normal epithelial cells into a-SMA-expres-
sing cells through EMyoT, a change that is suppressed by
FGFs secreted from cancer cells.
Cells that are located in or around tumour tissues and
express myoﬁbroblast markers, including a-SMA, calponin,
and desmin, are known as cancer-associated ﬁbroblasts
(CAFs) and have an important role in cancer progression
(Mueller and Fusenig, 2004; Orimo et al, 2005; Ostman and
Augsten, 2009). Thus, EMyoT mediated by cancer cells may
help generate CAFs. More interestingly, NMu-fb cells did not
express myoﬁbroblast markers but promoted the invasion of
MCF-7 cells much more potently than NMu-b cells expressing
myoﬁbroblast markers. Expression of MMP9, but not that of
MMP2, in MCF-7 cells was upregulated in the cells cocultured
with NMu-fb cells, compared with that in MCF-7 cells alone
(Supplementary Figure S6D). However, the increase in MMP9
expression may not be sufﬁcient to explain the phenomena.
Thus, the mechanism responsible for this process has not
been determined, and speciﬁc protein markers of NMu-fb
cells remain to be identiﬁed. Cancer cell invasion was re-
cently classiﬁed into two categories, so-called ‘collective
cancer cell invasion’ and ‘ﬁbroblast-led collective invasion’
(Gaggioli et al, 2007). The former is a phenomenon in which
cancer cells invade by themselves, while the latter highlights
the importance of certain ﬁbroblasts that initiate a collective
invasion chain of cancer cells. Although the speciﬁc ﬁbro-
blasts associated with ‘ﬁbroblast-led collective invasion’ have
not been identiﬁed, NMu-fb cells may function as these types
of ﬁbroblasts. Therefore, ﬁbroblastic and myoﬁbroblastic
cells generated from epithelial cells adjacent to tumours
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respectively, might have a unique role in cancer progression
that is distinct from those of ordinary ﬁbroblasts.
Materials and methods
Cell culture
All cells used in the present study were from the American Type
Culture Collection (Manassas, VA). The cell media and culture
conditions were previously described (Shirakihara et al, 2007).
NMuMG cells were cultured for several days and passaged every 2
days in medium with or without 1ng/ml TGF-b1, 30ng/ml FGF-2,
and 100mg/ml heparin. All cells were grown in a 5% CO2
atmosphere at 371C.
Reagents and antibodies
Recombinant human TGF-b1, FGF basic (FGF-2), and FGF-7 were
purchased from R&D Systems (Minneapolis, MN). SU5402, PI-103,
U73122, and GM6001 were purchased from Calbiochem (Darm-
stadt, Germany). U0126 was obtained from Promega (Madison,
WI). The mouse monoclonal anti-a-tubulin and anti-a-SMA
antibodies were purchased from Sigma-Aldrich. The mouse mono-
clonal anti-Erk2 antibody was from Millipore (Bedford, MA). The
rabbit polyclonal anti-phospho-Erk1/2 antibody was obtained from
Cell Signaling (Beverly, MA). The rabbit polyclonal anti-dEF1
antibody was from Santa Cruz Biotechnology (Lot No. E1408, Santa
Cruz, CA), and the mouse monoclonal anti-CtBP1 and anti-E-
cadherin antibodies were from BD Transduction Laboratory
(Lexington, KY). Rabbit monoclonal anti-calponin antibody was
from Abcam (Cambridge, UK). Tetramethylrhodamine isothiocya-
nate (TRITC)-conjugated phalloidin and propidium iodide (PI) were
from Sigma-Aldrich (Saint Louis, MO) and Molecular Probes
(Eugene, OR), respectively.
Immunoprecipitation, immunoblotting, and
immunoﬂuorescence labelling
The procedures used for immunoprecipitation, immunoblotting,
and immunoﬂuorescence were previously described (Shirakihara
et al, 2007). Immunodetection was performed with the ECL blotting
system (Amersham Bioscience, Piscataway, NJ) and Luminescent
Image Analyzer (LAS4000, Fujiﬁlm, Tokyo, Japan). Fluorescence
was examined using a confocal laser scanning microscope (Carl
Zeiss, Thornwood, NY).
RNA interference
siRNAs were transfected into cells according to the protocol
recommended for HiPerFect reagent (Qiagen, Valencia, CA).
NMuMG cells were transiently transfected with siRNAs against
mouse dEF1 (Stealth RNAi; Invitrogen, Carlsbad, CA), mouse SIP1
(GGAAAAACGUGGUGAACUA; B-Bridge, Sunnyvale, CA), or mouse
CtBP1 (Stealth RNAi; Invitrogen). The ﬁnal concentrations of the
siRNAs were 5nM, except for SIP1 siRNA, which had a ﬁnal
concentration of 10nM.
RNA extraction and RT–PCR
Total RNA was extracted and analysed by quantitative RT–PCR
analysis as previously described (Shirakihara et al, 2007). The
speciﬁcity of the detected signals was conﬁrmed by a dissociation
curve, which consisted of a single peak. Values were normalized to
the TATA-binding protein (TBP). Conventional RT–PCR analyses
were performed using the PC-708 Program Temp Control System
(ASTEC, Fukuoka, Japan). The RT–PCR primer sequences are listed
in Supplementary Table S1.
Cell motility assay
NMuMG cells were treated with TGF-b, FGF-2, or both for 4 days
and seeded in six-well tissue culture plates. The cell monolayers
were wounded by scratching with sterile plastic 200ml micropipette
tips and photographed using phase-contrast microscopy immedi-
ately and 12h after wounding. The assays were independently
performed in triplicate. The migration distance of each cell was
measured after the photographs were converted to Photoshop ﬁles
(Adobe, San Jose, CA).
Invasion assay
NMuMG cells were treated with TGF-b or both TGF-b and FGF-2 for
4 days and seeded onto Cell Culture Inserts (8mm pore size; BD
Falcon, Franklin Lakes, NJ) coated with Type IV collagen (BD
Biosciences, San Jose, CA). After 24h, the cells that had not invaded
into the lower surface of the ﬁlters were removed from the upper
face of the ﬁlters using cotton swabs. The cells that had invaded
into the lower surface of the ﬁlters were ﬁxed in methanol and
stained with Giemsa. Invasion was quantitated by visually counting
the photographed cells.
Collagen gel contraction assay
Type I collagen gel was prepared using an 8:1:1 ratio of cold
collagen solution (Cellmatrix I-P; Nitta Gelatin, Osaka, Japan), 10 
concentrated MEM (Invitrogen), and collagen dilution buffer
containing 0.05N NaOH, 2.2% NaHCO3, and 200mM HEPES, pH
7.4. NMuMG cell suspensions (2.0 10
5cells/200ml) were mixed in
800ml of the collagen gel solution. A measure of 1ml of the mixture
was added to each well of 12-well culture plates and allowed to
solidify at 371C for 30min. After solidiﬁcation, 1ml of DMEM
containing 4.5g/l glucose, 10% FBS, 10mg/ml insulin, 50U/ml
penicillin, and 50mg/ml streptomycin was overlaid to ﬂoat the gel.
The ﬂoating gels were incubated at 371Ci n5 %C O 2 for 2 days. The
gel surface area was quantiﬁed based on pixel number using ImageJ
(US National Institutes of Health, Bethesda, MD). The relative
changes in the surface area are reported as the percentage of the
original surface area.
Gelatin zymography
NMuMG cells were treated with TGF-b, FGF-2, or both for 4 days.
Then, the cells were cultured with serum-free media for 24h, and
the conditioned media were collected. Equal amounts of samples
were mixed with 3  non-reducing SDS–PAGE sample buffer. The
samples were applied to a 10% polyacrylamide gel impregnated
with 1mg/ml gelatin (Sigma). After running, SDS was removed
from the gel by washing three times with 2.5% Triton X-100
solution for 20min. Then, the gels were incubated overnight at 371C
in buffer containing 50mM Tris–HCl, pH 7.6, 5mM CaCl2, and
200mM NaCl. The gel was stained with 0.5% Coomassie blue
R250 (CBB) in 50% methanol and 5% acetic acid for 2h, and
subsequently destained with a solution containing 40% methanol
and 10% acetic acid.
In vitro three-dimensional invasion assay
A mixture of collagen I (Koken, Tokyo, Japan) and DMEM
containing 10% FBS, 10mM HEPES, and 0.1% sodium bicarbonate
were added to 12-well culture plates. The collagen gel was allowed
to solidify at 371C for 1h. The ﬁnal concentration of collagen gel
was 2.4mg/ml. MCF-7 cells stably expressing Ha-ras G12V were
infected with lentivirus encoding green ﬂuorescent protein (MCF-7-
GFP). NMuMG cells were pretreated with TGF-b or TGF-b and FGF-
2 for 2 days and then mixed with MCF-7-GFP cells and seeded on
collagen gels. The culture media containing each of the noted
ligands was changed every 2 days. After 1 week, the gels were ﬁxed
with Mildform (Wako, Osaka, Japan), embedded in parafﬁn, and
stained with haematoxylin–eosin (HE). The same sections were
used to detect GFP by confocal laser scanning microscopy.
Online supplemental material
Supplementary Figure S1 shows the effects of FGF-2 on TGF-b
signalling. Supplementary Figure S2 shows that FGF-2 prevents
EMyoT of a-TN4 cells, and Erk phosphorylation and miR-200b
expression in NMuMG cells. Supplementary Figure S3 shows the
interaction between CtBP1 and dEF1. Supplementary Figure S4
shows the role of dEF1 in EMT. Supplementary Figure S5 shows cell
proliferation of MCF-7 cocultured with NMuMG cells in collagen
gel. Supplementary Figure S6 shows that TGF-b and FGF-2 are
produced by cancer cells. Supplementary Table S1 lists the primers
used in this study.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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